Mass. movers

Piper analyst bullish on Infinity’s drug

Shares of Cambridge-based Infinity Pharmaceuticals Inc. rose after Piper Jaffray analyst M. Ian Somaiya said he believes the company’s experimental drug, IPI-145, will be approved to treat several types of cancer, with annual sales eventually approaching $3 billion. Infinity’s other drug, IPI-504, is in clinical testing as a treatment for lung cancer. The company is scheduled to report its fourth-quarter results on Tuesday. Analysts forecast a quarterly loss of 84 cents per share.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of